Hormonal
GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.
If you start a GLP-1 medication, expect digestive issues like nausea or diarrhea in the first few months. These symptoms are very common (affecting half to 60% of users) and are usually dose-dependent. The good news is that they typically get better over time. Starting with a lower dose and increasing slowly can help manage this.
Gastrointestinal (GI) disturbances are the most frequently reported adverse effects of GLP-1 receptor agonists (GLP-1RAs), including nausea, vomiting, diarrhea, constipation, and reflux. These effects are typically dose-dependent and constitute a major reason for treatment discontinuation. GI symptoms generally appear early in therapy, affecting approximately 50% to 60% of patients, but tend to diminish over time.
Why this rating
Based on a bibliometric analysis of 1075 articles, including systematic reviews and meta-analyses, though the paper itself is a bibliometric review, not a primary clinical trial.
Source
Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis
Riad Mohammed Abdelrahman et al. · INQUIRY The Journal of Health Care Organization Provision and Financing · 2026
DOI 10.1177/00469580261441498
More from this paper
- GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.Good
- GLP-1RAs are associated with rare but serious adverse events including acute pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, though causal relationships for some (like thyroid cancer) are not confirmed in humans.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →